Table 2b.
Serology results of convalescent patients by 30 days intervals since second first positive PCR test
| 0–29 | 30–59 | 60–89 | 90–119 | 120–149 | 150–179 | 180–209 | 210–239 | 240–269 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| N | 269 | 499 | 341 | 331 | 700 | 735 | 587 | 365 | 161 | |
| Age (in years) | 39.96 (14.78) | 41.10 (14.95) | 45.07 (16.53) | 43.52 (16.32) | 42.90 (16.23) | 40.95 (16.13) | 41.39 (16.14) | 40.59 (15.32) | 41.75 (17.42) | |
| Sex, n (%) | Female | 157 (58.4 %) | 326 (65.3 %) | 234 (68.6 %) | 219 (66.2 %) | 400 (57.1 %) | 461 (62.7 %) | 371 (63.2 %) | 230 (63.0 %) | 112 (69.6 %) |
| Male | 112 (41.6 %) | 173 (34.7 %) | 107 (31.4 %) | 112 (33.8 %) | 300 (42.9 %) | 274 (37.3 %) | 216 (36.8 %) | 135 (37.0 %) | 49 (30.4 %) | |
| SARS-CoV-2 IgG antibody level | mean (SD) | 1914 (3870) | 1739 (2972) | 1552 (2522) | 1195 (2406) | 1079 (2556) | 860 (1962) | 904 (2384) | 850 (2104) | 901 (1739) |
| median [IQR] | 490 [109–1869] | 586 [212–1908] | 538 [247–1723] | 377 [165–1080] | 329 [140–886] | 312 [138–8301] | 278 [125–751] | 278 [105–727] | 351 [124–919] |